Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

BW Higgs, Z Liu, B White, W Zhu, WI White… - Annals of the …, 2011 - ard.bmj.com
Objective To characterise activation of the type I interferon (IFN) pathway in patients with
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid …
被引用次数：428 相关文章

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

BW Higgs, Z Liu, B White, W Zhu… - Annals of the …, 2011 - search.proquest.com
Objective To characterise activation of the type I interferon (IFN) pathway in patients with
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid …

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

BW Higgs, Z Liu, B White, W Zhu… - Annals of the …, 2011 - pubmed.ncbi.nlm.nih.gov
Objective To characterise activation of the type I interferon (IFN) pathway in patients with
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid …

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

BW Higgs, Z Liu, B White, W Zhu, WI White… - Annals of the …, 2011 - hero.epa.gov
OBJECTIVE: To characterise activation of the type I interferon (IFN) pathway in patients with
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid …
[PDF] researchgate.net

[PDF][PDF] Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

BW Higgs, Z Liu, B White, W Zhu, WI White… - Ann Rheum …, 2029 - researchgate.net
Objective To characterise activation of the type I interferon (IFN) pathway in patients with
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid …

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.

BW Higgs, Z Liu, B White, W Zhu, WI White… - Annals of the …, 2011 - europepmc.org
Objective To characterise activation of the type I interferon (IFN) pathway in patients with
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid …

[引用][C] Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

BW Higgs, Z Liu, B White, W Zhu, WI White… - Annals of the …, 2011 - cir.nii.ac.jp
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma
share activation of a common type I interferon pathway | CiNii Research CiNii 国立情報学 …

[引用][C] Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

BW HIGGS, Z LIU, SA GREENBERG… - Annals of the …, 2011 - pascal-francis.inist.fr
Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma
share activation of a common type I interferon pathway CNRS Inist Pascal-Francis CNRS …

Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

BW Higgs, Z Liu, B White, W Zhu, WI White… - Annals of the …, 2011 - ard.bmj.com
Objective To characterise activation of the type I interferon (IFN) pathway in patients with
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid …
[PDF] academia.edu

[PDF][PDF] Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway

BW Higgs, Z Liu, B White, W Zhu, WI White… - Ann Rheum …, 2029 - academia.edu
Objective To characterise activation of the type I interferon (IFN) pathway in patients with
systemic lupus erythematosus (SLE), dermatomyositis (DM), polymyositis (PM), rheumatoid …